Pharmacokinetics of noopept and its active metabolite cycloprolyl glycine in rats


1. Zakusov Research Institute of Pharmacology, Moscow, Russia
Type: Short communication
DOI: 10.18097/PBMC20186405455      PubMed Id: 30378564
Year: 2018 vol: 64  issue:5  pages: 455-458
Abstract: The study of the pharmacokinetics of new drugs and the identification of active metabolites is a necessary step for effective and safe use in the clinical practice. It is especially important for peptide drugs due to their enzymatic instability, low bioavailability and poor permeability through the blood-brain barrier (BBB). The role of endogenous neuropeptides containing cyclic amino acids, proline, pyroglutamic acid, and glycine, in the regulation of memory processes is known as terminal peptide fragments. The development of nootropic drugs based on natural neuropeptides with high pharmacological activity and improved pharmacokinetic properties (enzymatic stability, high bioavailability, and good permeability through the BBB) is an important problem of modern neuropsychopharmacology. Developed drugs – representing short (di- and tri-) peptides appear to meet these requirements. In the Zakusov Research Institute of Pharmacology a nootropic agent noopept (N-phenylacetyl-prolyl-L-glycine ethyl ester), was developed and introduced into medical practice, studies of its pharmacokinetics in ratsrevealed that the noopept metabolite found in the rat plasma and brain, cyclo-prolyl-L-glycine (CPG), differed significantly in its pharmacokinetic parameters from noopept, but at the same time it had similar noopept multi-component spectrum of pharmacological action, namely the influence on higher integrative functions of memory.
Download PDF:
Reference: Boyko S.S., Zherdev V.P., Shevchenko R.V., Pharmacokinetics of noopept and its active metabolite cycloprolyl glycine in rats, Biomeditsinskaya khimiya, 2018, vol: 64(5), 455-458.
 In press